Categories: News

Announcing a digital health ‘therable’ for pain relief

SEATTLE, Jan. 12, 2021 /PRNewswire/ — The 50 million Americans who suffer with chronic pain will soon have a drug-free alternative to provide relief.  Today, Soovu Labs, Inc. moves out of stealth mode to announce the introduction of Soovu™ Wearable Pain Relief, a unique “therable” (wearable medical device and app) to treat chronic pain.

In the U.S. more money is spent on pain treatments and lost productivity than diabetes, cancer and heart disease combined. Clearly opioids are not the answer, and recently the FDA required NSAIDs, like Aleve and Advil, to include heart attack and stroke warnings on their labels. According to Chuck Chabal, MD and Co-Founder of Soovu Labs, “In the COVID era, pain complaints are up by 50%, as are comorbidities of anxiety, stress and depression. The need for transformation in the management of pain has never been greater.”

With funding from the National Institutes of Health, Dr. Chabal and fellow researcher and Co-Founder Dr. Peter Dunbar developed a drug-free, wearable for on-the-go relief.  These doctors discovered that pulsing high levels of heat on the skin desensitized the “TRPV1” receptor, and in so doing provided immediate and long-lasting relief of chronic pain1. Published, independent clinical studies confirmed that Soovu significantly reduced chronic pain compared to a placebo device. The Soovu companion app provides digital coaching to reduce stress and anxiety associated with pain, and sends results to the cloud for machine learning for personalized treatments. The device and app uniquely address both physiological and psychological pathways to pain relief. 

Soovu Labs is currently completing a round of funding to scale up production. With its launch of Soovu Wearable Pain Relief in fall 2021, the company is poised to reduce the pain of millions of Americans and increase the possibilities in their lives.  

Soovu Labs, Inc. is on a mission to transform the treatment of chronic pain without drugs, invasive procedures or surgery.  Their first product, Soovu Wearable Pain Relief, will target treatment of chronic back and neck pain. To learn more, visit www.soovu.com.  Inquiries from institutions or accredited investors may be addressed to Allan Stephan, CEO, at als@soovu.com

Soovu Wearable Pain Therapy is indicated to provide topical heating for the purpose of elevating tissue temperature for the temporary relief of minor muscle and joint pain and stiffness; the temporary relief of joint pain associated with arthritis; the temporary relief of muscle spasms, minor sprains and strains, and minor muscular back pain; the temporary relief of menstrual discomfort; the relaxation of muscles; and the temporary increase of local circulation where applied.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/announcing-a-digital-health-therable-for-pain-relief-301206694.html

SOURCE Soovu Labs

Staff

Recent Posts

Health Care AI Initiative Launched by Paragon Health Institute

New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…

13 minutes ago

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…

13 minutes ago

CelLBxHealth PLC Announces Board Changes

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

3 hours ago

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

4 hours ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

18 hours ago